Varian, a Siemens Healthineers (ETR:SHL) company, on Tuesday announced the European launch of IntelliBlate, a CE-marked microwave ablation solution for soft tissue tumour treatment.

IntelliBlate integrates with Siemens Healthineers' image-guided therapy technologies, allowing clinicians to plan, place, treat, monitor and confirm ablation in a single clinical environment.

The system offers precision-driven, minimally invasive treatment, featuring dual generators, real-time temperature monitoring via the Ximitry probe, and a compact, intuitive design for simplified workflow and faster setup.

IntelliBlate supports large, controlled spherical ablation zones, offering tailored treatment options for individual patient needs. The product builds on US FDA clearance received in 2024 and arrives in Europe amid growing clinical evidence supporting thermal ablation as a first-line option, as highlighted in the COLLISION phase 3 trial published in The Lancet Oncology.

Varian will introduce IntelliBlate to the European clinical community at CIRSE 2025, with hands-on demonstrations and training sessions.